Using hyaluronic acid gel to prevent adhesions after surgery for retained pregnancy tissue
The Efficacy of Auto-crosslinked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception:a Randomized Controlled Trial
This study is testing if a special gel can help prevent complications like infertility after surgery for leftover pregnancy tissue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 86 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | Fu Xing Hospital, Capital Medical University Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05085067 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of auto-cross linked hyaluronic acid gel in preventing the reformation of intrauterine adhesions following hysteroscopic resection of retained products of conception (RPOC). RPOC can lead to complications such as infertility and menstrual abnormalities if not treated properly. The study will randomly assign patients who have undergone the surgical procedure to receive either the gel or standard care, allowing for a comparison of outcomes related to adhesion formation. The goal is to determine if the gel can reduce the risk of complications associated with RPOC treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with retained products of conception who are undergoing hysteroscopic resection.
Not a fit: Patients with severe complications from surgery or those with active genital tract infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve fertility outcomes for patients who have experienced retained products of conception.
How similar studies have performed: While the use of hyaluronic acid gel in this context is promising, similar studies have shown mixed results, indicating that this approach may still be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of retained products of conception * Written consent obtained Exclusion Criteria: * Patients with severe complications of medicine and surgery * Acute or chronic genital tract inflammation * No understanding or approving the randomized controlled trial
Where this trial is running
Beijing, Beijing Municipality
- FuxingHospital，Captital Medical University — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xue Yang, Master
- Email: yuanxy515@163.com
- Phone: 8618810957056
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.